Sunshine Biopharma to Re-Domicile in Canada for Expansion and Financing Opportunities for Adva-27a Cancer Drug Candidate
December 02 2013 - 8:00AM
Marketwired
Sunshine Biopharma to Re-Domicile in Canada for Expansion and
Financing Opportunities for Adva-27a Cancer Drug Candidate
MONTREAL, QC--(Marketwired - Dec 2, 2013) - Sunshine Biopharma
Inc. (OTCQB: SBFM), a pharmaceutical company focused on the
research, development and commercialization of drugs for the
treatment of various forms of cancer, today announced that it is
re-domiciling the Company in Canada for expansion through
acquisitions and to gain access to various financing opportunities
available to Canadian corporations. To this end, The Company filed
a Schedule 14-C Information Statement on September 16, 2013 and an
S-4 Registration Statement on October 23, 2013.
"We are very pleased that the re-domiciling process is going
smoothly," said Dr. Steve N. Slilaty, Chief Executive Officer of
Sunshine Biopharma. "Re-domiciling the Company in Canada will give
us access to a more favorable fiscal environment and provide with
greater flexibility to execute our business plan. This will better
position our Company for expansion and allow us to capitalize on
growth opportunities as our Adva-27a drug candidate enters the
clinic."
About Adva-27a Adva-27a is Sunshine Biopharma's lead anticancer
compound, a small molecule that has recently been shown to be
effective at killing multidrug resistant breast cancer cells,
small-cell lung cancer cells, uterine sarcoma cells and pancreatic
cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages
4423-4432, October 2012). Adva-27a is currently in the IND-Enabling
stage of development. The original U.S. patent covering Adva-27a
was issued on August 7, 2012 under US patent number 8,236,935.
Safe Harbor Forward-Looking Statements To the extent that
statements in this press release are not strictly historical,
including statements as to revenue projections, business strategy,
outlook, objectives, future milestones, plans, intentions, goals,
future financial conditions, future collaboration agreements, the
success of the Company's development, events conditioned on
stockholder or other approval, or otherwise as to future events,
such statements are forward-looking, and are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The forward-looking statements contained in this
release are subject to certain risks and uncertainties that could
cause actual results to differ materially from the statements
made.
For Additional Information Contact: Camille Sebaaly CFO Sunshine
Biopharma Inc. Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com www.sunshinebiopharma.com